𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Ketoacidosis and lactic acidosis – frequent causes of death in chronic alcoholics?

✍ Scribed by B. Brinkmann; G. Fechner; B. Karger; A. DuChesne


Publisher
Springer-Verlag
Year
1998
Tongue
German
Weight
102 KB
Volume
111
Category
Article
ISSN
0937-9827

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Alcoholic ketoacidosis as a cause of dea
✍ Jørgen L. Thomsen; Søren Felby; Peter Theilade; Erik Nielsen 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 484 KB

Forensic pathologists are familiar with alcohol abusers, who are found dead and in whom the cause of death cannot be ascertained. In order to examine the possible role of ketoacidosis for the cause of death in this group of alcohol abusers, the concentrations of ketone bodies (acetone, acetoacetate,

The manner and cause of death in a foren
✍ Anders U. Hansen; Jørn Simonsen 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 540 KB

Chronic alcoholics account for an increasing number of the cases which are examined in forensic pathology. The manner and cause of death in 122 chronic alcoholics is described and compared with a previous investigation and to a group of non-alcoholics. The percentage of cases in which the manner of

Ischemic heart disease and epilepsy: two
✍ Hans Denison; Adam Berkowicz; Christer Wendestam; Sven Wallerstedt 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 692 KB

The objectives of this research were to study the distribution of in- and out-hospital deaths and causes of death in male alcoholics and in particular to analyze obscure cases. In a population-based sample of 1123 men treated in one detoxification unit during 1986-1989, 97 patients with alcohol depe

Severe lactic acidosis during treatment
✍ Christian M. Lange; Jörg Bojunga; Wolf Peter Hofmann; Katrin Wunder; Ulrike Mihm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

Entecavir is a potent nucleoside inhibitor of the hepatitis B virus (HBV) polymerase with a high antiviral efficacy and a high genetic barrier to viral resistance. After approval in 2006, knowledge on the side effect profile in patients with advanced liver disease and impaired liver function is stil